Recce Pharmaceuticals is nearing the completion of its Phase 2 clinical trial evaluating RECCE 327 Topical Gel (R327G) for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). The trial's interim data suggests promising efficacy and a favorable safety profile for the novel topical gel.
Positive Interim Results
According to Recce Pharmaceuticals, 20 out of the planned 30 patients have been dosed in the Phase 2 trial. The interim data indicates a strong therapeutic response, with all patients completing treatment with R327G achieving positive outcomes, demonstrating either complete cure or notable improvement. Importantly, no Serious Adverse Events (SAEs) have been reported in association with R327G treatment.
Expert Commentary
Dr. Alan W Dunton, Recce's chief medical advisor, commented on the interim results, stating, "These interim results reflect a remarkable advancement in our journey to address critical unmet medical needs in anti-infective therapies. The robust response we are seeing with R327G is encouraging, especially as we near completion of the Phase II trial. Achieving a response of complete cure or notable improvement in all patients treated so far highlights the potential impact of R327G in treating complex bacterial infections, including diabetic foot infections."
Addressing Unmet Needs in ABSSSI
ABSSSI represents a significant clinical challenge, with a need for novel anti-infective therapies. Recce Pharmaceuticals is focused on delivering a pioneering, synthetic anti-infective topical therapy to address ABSSSI as the trial progresses towards completion within the current calendar.
